Kura Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Kura Oncology's estimated annual revenue is currently $5.7M per year.
- Kura Oncology received $Undisclosed in venture funding in August 2017.
- Kura Oncology's estimated revenue per employee is $38,233
- Kura Oncology's total funding is $791.4M.
- Kura Oncology's current valuation is $907.8M. (January 2022)
Employee Data
- Kura Oncology has 150 Employees.
- Kura Oncology grew their employee count by 9% last year.
Kura Oncology Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.7M | 61 | 9% | $53M | N/A |
#2 | $34.3M | 177 | 17% | $110M | N/A |
#3 | $0.4M | 273 | 5% | $236.7M | N/A |
#4 | $34.5M | 178 | -5% | $160M | N/A |
#5 | $3.7M | 24 | 20% | N/A | N/A |
#6 | $147.3M | 321 | 2% | $192.5M | N/A |
#7 | $17.5M | 113 | -3% | $24.1M | N/A |
#8 | $2.7M | 43 | 79% | N/A | N/A |
#9 | $34.1M | 220 | 100% | N/A | N/A |
#10 | $47.1M | 304 | -3% | N/A | N/A |
What Is Kura Oncology?
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development. For additional information, please visit our website at www.kuraoncology.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$791.4M
Total Funding
150
Number of Employees
$5.7M
Revenue (est)
9%
Employee Growth %
$907.8M
Valuation
N/A
Accelerator
Kura Oncology News
Kura Oncology Inc (KURA) stock is lower by -40.33% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy...
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The...
On Thursday, shares of Kura Oncology, Inc. (NASDAQ:KURA) marked $16.14 per share versus a previous $15.24 closing price. With having a ...
03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $44.6M | 150 | 10% | N/A |
#2 | $3.5M | 151 | 19% | N/A |
#3 | $31.6M | 151 | 18% | N/A |
#4 | $22.1M | 151 | 16% | N/A |
#5 | $39.4M | 151 | 26% | N/A |
Kura Oncology Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-16 | $60.0M | Undisclosed | Article | |
| 2015-10-30 | $60.0M | Undisclosed | Citigroup | Article |
| 2017-08-11 | $Undisclosed | Undisclosed | Leerink Partners | Article |
